ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.
Journal articles
- Editorial
Lesnock, J; Gaillard, S; Tew, WP
Published in: Gynecol Oncol
January 2026
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Gynecol Oncol
DOI
EISSN
1095-6859
Publication Date
January 2026
Volume
204
Start / End Page
251 / 253
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lesnock, J., Gaillard, S., & Tew, W. P. (2026). ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement. Gynecol Oncol, 204, 251–253. https://doi.org/10.1016/j.ygyno.2025.12.004
Lesnock, Jamie, Stéphanie Gaillard, and William P. Tew. “ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.” Gynecol Oncol 204 (January 2026): 251–53. https://doi.org/10.1016/j.ygyno.2025.12.004.
Lesnock J, Gaillard S, Tew WP. ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement. Gynecol Oncol. 2026 Jan;204:251–3.
Lesnock, Jamie, et al. “ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.” Gynecol Oncol, vol. 204, Jan. 2026, pp. 251–53. Pubmed, doi:10.1016/j.ygyno.2025.12.004.
Lesnock J, Gaillard S, Tew WP. ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement. Gynecol Oncol. 2026 Jan;204:251–253.
Published In
Gynecol Oncol
DOI
EISSN
1095-6859
Publication Date
January 2026
Volume
204
Start / End Page
251 / 253
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences